News Room

DPP HIV-SYP

Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System

| Chembio | No Comments
HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission to the U.S. Food and Drug Administration (FDA) for a Clinical…

Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

| Chembio | No Comments
HAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it was awarded a $3.2 million contract from the Centers for Disease Control…

Chembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial Channel

| Chembio | No Comments
Initiates distribution of SCoV-2 Ag Detect Self-Test to consumers in the United States and expansion of SURE CHECK HIV Self-Test distribution to consumers in Brazil and the United Kingdom HAUPPAUGE,…

Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors

| Chembio | No Comments
HAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the election of Leslie Teso-Lichtman to its Board of Directors at Chembio’s 2022…
Chembio Employees Working in the Lab

Chembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia Facility

| Chembio | No Comments
HAUPPAUGE, N.Y. , May 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has entered into…
COVID-19 Nasal Swab Test Image

Chembio Announces EUA Submission for DPP Respiratory Antigen Panel: Test Provides Simultaneous Detection of Flu A, Flu B, and SARS-CoV-2

| Chembio | No Comments
HAUPPAUGE, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization…
Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay

Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay

| Chembio | No Comments
HAUPPAUGE, N.Y., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of commercial distribution of an…
NACCHO Webinar Image

Preparing for the 2021-2022 Flu Season: What to Expect, and How to Plan Webinar

| Chembio | No Comments
Status™ COVID-19/FLU Product COVID-19 has shown us that early detection and response is essential to curbing the spread of infectious diseases. Experts say the 2021-2022 Flu and Respiratory season will…

Watch the recorded Webinar, Fighting the Syphilis & HIV Epidemics: Voices from the Field

| Chembio | No Comments
Date: May 27th, 2021Time: 2:30pm-3:45pm ESTHost: National Coalition of STD Directors   Description The National Coalition of STD Directors, in partnership with Chembio, is excited to present an informational webinar…